What Quanterix (QTRX) Said on Its Q3 Earnings Call

Quanterix (QTRX) reported a Q3 net loss of $21.6M, improved from last year. Adjusted EBITDA loss was $12.2M. Gross margin rose to 47.4%. LucentAD test volume doubled, but revenue from diagnostics fell to $1.2M. The company expects 2026 gross margin of 48-50% and $70M cash. Alzheimer's test discussions with FDA continue, with no clearance date given.

Original reporting
Published Nov 9, 2026, 4:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 4:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Quanterix (QTRX) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$QTRXBearishMed
01

Why it matters

The earnings release adds new financial data and guidance, which is the primary catalyst for short‑term trading decisions.

02

Market read

First‑time earnings disclosure for Q3, providing fresh guidance and cash outlook for investors.

03

What to watch

Potential upside from new Medicaid reimbursement and upcoming FDA discussions may not be fully priced in.

Relevance 7/10Novelty 7/10Timing: post‑earnings release today

Background

Quanterix is a life‑sciences company developing ultra‑sensitive immunoassay platforms; the Q3 call covered financial results and product updates.

Company-level read

Ticker impact

$QTRXBearishHigh confidence
Context

Quanterix reported Q3 net loss of $21.6M, updated guidance and cash outlook, making the earnings release the primary news for the ticker.

Expected impact

likely modest pressure as the market prices in the loss and unchanged guidance

Evidence & confidence

The company posted a larger-than-expected loss, but maintained its cash and margin guidance, which typically limits large moves.

Market effects

Provides insight into the diagnostics and biotech instrumentation sector's margin pressures.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact beyond niche diagnostic market participants.

Counterpoint

If investors focus on cash runway and upcoming product launches, the stock could be undervalued despite the loss.

Key entities

  • Quanterix Corporation

    NASDAQ‑listed diagnostics platform provider.

Related articles

$QTRXMed

Quanterix Releases Financial Results for the Third Quarter of 2026

Quanterix Corp (QTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quanterix Releases Financial Results for the Third Quarter of 2026 Reports $35.0 million in revenue, up 6.3% sequentially, and $80.7 million of cash and marketable securities Initiatives to accelerate commercial effectiveness position the Company for growth in rest o

$QTRXHighAI 9/10

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Quanterix (QTRX) said Q2 2026 revenue was about $3 million (9%) below May guidance, citing broad-based shortfalls and commercial execution challenges. The company lowered 2026 revenue guidance to $142 million to $148 million from $169 million to $174 million and expects ~$80 million cash by year-end. Quanterix added commercial leaders (Jim Gute, Geoff Albrecht) and reorganized sales, citing Akoya integration savings of $85 million annually.

$QTRXMed

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test

Quanterix (QTRX) said it completed Akoya Biosciences integration in Q2 and delivered $85M in revenue synergies. It is reshaping sales teams and expects clinical-trial bookings to rise QoQ. For its LucentAD Complete Alzheimer’s blood test, Quanterix filed a 510(k) in January and targets an FDA decision in Q4, possibly into Q1, citing a CMS price crosswalk of $897. It targets $10M diagnostics revenue in 2026.

$QTRXMed

Quanterix Q2 Earnings Call Highlights

Quanterix (NASDAQ:QTRX) reported Q2 cash use of $5.7M and cash of $96.9M. Simoa revenue was $20.6M, Spatial $12.3M, and GAAP gross margin 38.5%. Management guided Q3 revenue flat to slightly above Q2 and cited Akoya integration, $85M annualized savings, and commercial reorganization. FDA timing for LucentAD Complete is targeted for late 2026.